Nanobiotech in big pharma: a business perspective.
Since the early 2000s, numerous publications have presented major scientific opportunities that can be achieved through integrating insights from the area of nanotech into biotech (nanobiotech). This paper aims to explore the economic significance that nanobiotech has gained in the established pharmaceutical industry (big pharma). The empirical investigation draws on patent data as well as product revenue data; and to put the results into perspective, the amounts are compared with the established/traditional biotech sector. The results indicate that the new technology still plays only a minor role - at least from a commercial perspective.
Swiss Federal Institute of Technology (ETH) Zurich; Department of Management, Technology, and Economics; Group for Technology and Innovation Management; Weinbergstrasse 56/58, CH-8092 Zurich, Switzerland.
Martin
M
Würmseher
Venture Foundation, Schwimmbadstrasse 1, CH-5210 Windisch, Switzerland.
Lea
L
Firmin
D001709:Biotechnology / Q000191:economics* / Q000639:trends; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D006801:Humans; D036103:Nanotechnology / Q000191:economics* / Q000639:trends; D012106:Research / Q000191:economics*
business development; commercialization; economic significance; general purpose technology; nanobiotech; patent classification; patents; product revenues